Abstract | OBJECTIVE: METHODS: The records of patients who had received a 7-day course of terconazole cream for culture-proved non-C. albicans vaginitis were reviewed. Data with regard to patient demographics, clinical and mycologic response to therapy within 1 month of treatment, and outcome with other antifungal therapies were analyzed. RESULTS: Twenty-eight patients received terconazole cream for non-C. albicans infections. Three patients did not return for follow-up. The median age was 45 years. Seven (28%) patients were nulliparous. The median duration of symptoms was 3 years. Nine patients (36%) had received terconazole within the 6 months prior to referral. Overall, there were 20 C. glabrata cases, 3 C. parapsilosis, and 2 C. lusitaniae. Fourteen (56%) patients achieved a mycologic cure; 11 (44%) noted a resolution of their symptoms. Prior terconazole use was not associated with treatment failure (P = 0.09). Ten failures received boric acid suppositories as subsequent treatment; a cure was effected in 4 (40%). Two of three patients (67%) were eventually cured with flucytosine cream. Five (20 %) patients remained uncured. CONCLUSIONS:
Terconazole cream may be an appropriate first-line treatment for non C. albicans vaginitis, even in patients who have previously received the drug.
|
Authors | G Sood, P Nyirjesy, M V Weitz, A Chatwani |
Journal | Infectious diseases in obstetrics and gynecology
(Infect Dis Obstet Gynecol)
Vol. 8
Issue 5-6
Pg. 240-3
( 2000)
ISSN: 1064-7449 [Print] Egypt |
PMID | 11220485
(Publication Type: Journal Article)
|
Chemical References |
- Antifungal Agents
- Boric Acids
- Triazoles
- Vaginal Creams, Foams, and Jellies
- terconazole
- Flucytosine
|
Topics |
- Antifungal Agents
(pharmacology, therapeutic use)
- Boric Acids
(administration & dosage)
- Candidiasis, Vulvovaginal
(drug therapy)
- Female
- Flucytosine
(administration & dosage)
- Humans
- Middle Aged
- Retrospective Studies
- Treatment Outcome
- Triazoles
(pharmacology, therapeutic use)
- Vaginal Creams, Foams, and Jellies
|